Skip to content

Assessment of Perinatal Outcome after Sustained Tocolysis in Early Labour (APOSTEL II)

Assessment of Perinatal Outcome after Sustained Tocolysis in Early Labour (APOSTEL II) - APOSTEL II

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30860
Enrollment
400
Registered
2008-01-14
Start date
2008-05-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

threatened preterm labour

Interventions

Prior to randomization, all patients will undergo measurement of cervical length and, in case of unruptured membranes, measurement of cervical fibronectin and vaginal examination. All women will the

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Women with a gestational age between 24+0 and 31+6 weeks who are spontaneously in labour, and who have been treated for 48 hours with tocolytics.

Exclusion criteria

Exclusion criteria: Women with signs of intra-uterine infection, women whose child has signs of fetal distress (abnormal CTG or biophysical profile) or major congenital malformation and women with any contraindication for the use of nifedipine or having a maternal disease (severe hypertension, HELLP syndrome, preeclampsia or other) or other reason for delivery.

Design outcomes

Primary

MeasureTime frame
The main outcome measure will be a composite neonatal morbidity status, including perinatal death, chronic lung disease (CLD) and severe respiratory distress syndrome (IRDS), intra ventricular hemorrhage (IVH) grade 3 and 4, periventricular leukomalacia (PVL) and necrotizing enterocolitis (NEC) at the calculated term date.

Secondary

MeasureTime frame
Secondary outcomes will be gestational age at delivery, number of days in NICU, and total days in hospital and costs.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)